Depomed Inc (DEPO) 12.87 $DEPO
Why DepoMed Inc. Shares Temporarily Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 14, 12:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DepoMed , a biopharmaceutical company...
Depomed Announces Settlements with Two Gralise® ANDA Filers
PR Newswire - Mon Apr 14, 7:00AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The patent litigation continues against Actavis, the other Gralise ANDA filer.
Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Today's Dead Cat Bounce Stock Is DepoMed (DEPO)
at The Street - Fri Apr 04, 9:17AM CDT
Trade-Ideas LLC identified DepoMed (DEPO) as a "dead cat bounce" (down big yesterday but up big today) candidate
5 Stocks Poised for Breakouts
at The Street - Fri Mar 28, 1:42PM CDT
These stocks look ready to break out and trade higher from current levels.
Depomed A 'Turtle' Gaining In Specialty Pharma Race
at Investor's Business Daily - Tue Mar 25, 4:52PM CDT
Specialty pharmaceutical company Depomed has been around nearly 20 years. But as CEO James Schoeneck says, it has only just begun to realize its potential. Of the four drugs in its product portfolio, three were acquired since 2012. The most recent,...
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
Correction: Wall Street Stocks story
AP - Thu Mar 13, 12:08PM CDT
NEW YORK (AP) — NEW YORK (AP) — In a story March 11 that included an item about the company Depomed, The Associated Press erroneously reported that Depomed had received a $10 million payment after one of its drugs was approved. The payment actually was for the approval of another company's drug that is used in combination with a polymer coating produced by Depomed.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
PulteGroup and Herbalife are big market movers
AP - Wed Mar 12, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily XXX on the New York Stock Exchange and the Nasdaq Stock Market:
Depomed Earns $10 Million Milestone for FDA Approval of Mallinckrodt's XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII)
PR Newswire - Wed Mar 12, 7:45AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced that the U.S. Food and Drug Administration (FDA) approved Mallinckrodt plc's New Drug Application (NDA) for XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), previously known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would otherwise be inadequate. The release profile of XARTEMIS XR combines Mallinckrodt's newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed's advanced Acuform® drug delivery technology.
Depomed To Report Fourth Quarter Fiscal Year 2013 Financial Results On Wednesday, March 12, 2014
PR Newswire - Mon Mar 10, 4:30PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it will release fourth quarter fiscal year 2013 financial results after the market closes on Wednesday, March 12, 2014. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm Pacific time to discuss its results.
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Depomed To Present At The 26th Annual ROTH Conference On Monday, March 10, 2014
PR Newswire - Wed Mar 05, 3:15PM CST
Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the 26th Annual ROTH Conference on Monday, March 10, 2014, at the Ritz Carlton in Dana Point, California.
Depomed, Foot Locker, Oclaro, Mueller Water Products and Magna Intl. Reached New 52-Week High
PR Newswire - Wed Mar 05, 12:40PM CST
Editor Note: For more information about this release, please scroll to bottom.
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sappi Fine Paper North America Announces New Dual Purpose Digital Sheet - Opus® DX
PR Newswire - Tue Mar 04, 7:57AM CST
Sappi Fine Paper North America today launched Opus DX - a cross platform #2 digital cut sheet offering supreme versatility with performance on both dry and liquid toner presses including HP® Indigo, Kodak NexPress, Xerox® iGen3® and Xerox® iGen4®, as well as Canon, Ricoh®, and Konica Minolta bizhub® digital presses. With this launch, the Opus brand just got stronger allowing high-value bundling opportunities across the Opus digital, folio sheet and web lines, perfect for corporate paper programs demanding an optical match in one brand.
3 Stocks Spiking on Unusual Volume
at The Street - Tue Mar 04, 5:00AM CST
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Mar 03, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why DepoMed Inc. Shares Temporarily Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 14, 12:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DepoMed , a biopharmaceutical company...
Depomed Announces Settlements with Two Gralise® ANDA Filers
PR Newswire - Mon Apr 14, 7:00AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The patent litigation continues against Actavis, the other Gralise ANDA filer.
Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Today's Dead Cat Bounce Stock Is DepoMed (DEPO)
at The Street - Fri Apr 04, 9:17AM CDT
Trade-Ideas LLC identified DepoMed (DEPO) as a "dead cat bounce" (down big yesterday but up big today) candidate
5 Stocks Poised for Breakouts
at The Street - Fri Mar 28, 1:42PM CDT
These stocks look ready to break out and trade higher from current levels.
Depomed A 'Turtle' Gaining In Specialty Pharma Race
at Investor's Business Daily - Tue Mar 25, 4:52PM CDT
Specialty pharmaceutical company Depomed has been around nearly 20 years. But as CEO James Schoeneck says, it has only just begun to realize its potential. Of the four drugs in its product portfolio, three were acquired since 2012. The most recent,...
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
Correction: Wall Street Stocks story
AP - Thu Mar 13, 12:08PM CDT
NEW YORK (AP) — NEW YORK (AP) — In a story March 11 that included an item about the company Depomed, The Associated Press erroneously reported that Depomed had received a $10 million payment after one of its drugs was approved. The payment actually was for the approval of another company's drug that is used in combination with a polymer coating produced by Depomed.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
PulteGroup and Herbalife are big market movers
AP - Wed Mar 12, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily XXX on the New York Stock Exchange and the Nasdaq Stock Market:
Depomed Earns $10 Million Milestone for FDA Approval of Mallinckrodt's XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII)
PR Newswire - Wed Mar 12, 7:45AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced that the U.S. Food and Drug Administration (FDA) approved Mallinckrodt plc's New Drug Application (NDA) for XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), previously known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would otherwise be inadequate. The release profile of XARTEMIS XR combines Mallinckrodt's newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed's advanced Acuform® drug delivery technology.
Depomed To Report Fourth Quarter Fiscal Year 2013 Financial Results On Wednesday, March 12, 2014
PR Newswire - Mon Mar 10, 4:30PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it will release fourth quarter fiscal year 2013 financial results after the market closes on Wednesday, March 12, 2014. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm Pacific time to discuss its results.
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Depomed To Present At The 26th Annual ROTH Conference On Monday, March 10, 2014
PR Newswire - Wed Mar 05, 3:15PM CST
Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the 26th Annual ROTH Conference on Monday, March 10, 2014, at the Ritz Carlton in Dana Point, California.
Depomed, Foot Locker, Oclaro, Mueller Water Products and Magna Intl. Reached New 52-Week High
PR Newswire - Wed Mar 05, 12:40PM CST
Editor Note: For more information about this release, please scroll to bottom.
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sappi Fine Paper North America Announces New Dual Purpose Digital Sheet - Opus® DX
PR Newswire - Tue Mar 04, 7:57AM CST
Sappi Fine Paper North America today launched Opus DX - a cross platform #2 digital cut sheet offering supreme versatility with performance on both dry and liquid toner presses including HP® Indigo, Kodak NexPress, Xerox® iGen3® and Xerox® iGen4®, as well as Canon, Ricoh®, and Konica Minolta bizhub® digital presses. With this launch, the Opus brand just got stronger allowing high-value bundling opportunities across the Opus digital, folio sheet and web lines, perfect for corporate paper programs demanding an optical match in one brand.
3 Stocks Spiking on Unusual Volume
at The Street - Tue Mar 04, 5:00AM CST
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Mar 03, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
